https://www.youtube.com/watch?v=NO-s2sU-Tus This is a video from Experts On CTEPH, where you can watch Dr. Victor F. Tapson, MD, of Cedars-Sinai Medical Center, LA, talk about his experience of how CTEPH develops and manifests along with other important facts on how to distinguish CTEPH from PAH. Learn more…

People with chronic thromboembolic pulmonary hypertension (CTEPH) have significantly worse quality of life at their initial assessment, and higher hospitalization rates over time, relative to idiopathic pulmonary arterial hypertension (IPAH) patients, according to a multicenter study in the U.S. Notably, these quality-of-life differences disappeared over time, and CTEPH…

Quality of life is an important measure of patient health and treatment effectiveness, but often overlooked in people with chronic thromboembolic pulmonary hypertension (CTEPH). A review of such measurements in this patient group found plenty of room for improvement both in tools selected and their use — and called for more research on the…

https://vimeo.com/184579437 In this video from Elsevier Pharma Solutions, Professor Marc Humbert discusses the diagnostic processes for pulmonary hypertension and chronic thromboembolic pulmonary hypertension (CTEPH)—which is a curable form of the disease. RELATED: A study find international diagnosis and management of CTEPH is inadequate. Prof. Hubert explains that CTEPH is…

Researchers at University of California, San Diego (UCSD) recently published findings in the journal Pulmonary Circulation revealing the prevalence of specific collateral arteries in patients with chronic thromboembolic pulmonary hypertension (CTEPH). The study is entitled “Prevalence of coronary artery-pulmonary artery collaterals in patients with chronic…

Treatment with treprostinil improved the risk profile in people with inoperable or persistent severe chronic thromboembolic pulmonary hypertension (CTEPH). The risk profile was assessed using a risk score established to predict a response to treatment and survival in people with pulmonary arterial hypertension (PAH), the most common type…

Patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are successfully treated with pulmonary endarterectomy (PEA) may be at increased risk of having low levels of oxygen in the blood due to severe pulmonary arteriopathy, a condition characterized by pulmonary artery remodeling, according to a study from Chiba University in Japan. The…

A research journal recently reviewed the use of balloon pulmonary angioplasty (BPA), a new option for people with inoperable chronic thromboembolic pulmonary arterial hypertension. The work, titled “Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension“ appeared in the July 7, 2015 issue of…

According to a recent study published in the journal Heart, RV afterload increases in patients with chronic thromboembolic pulmonary hypertension (CTEPH) during exercise, resulting in a marked reduction in RVEF and SV reserve. However, sildenafil may reverse this effect. In patients with…

Inhalation treatment that uses either nitric oxide or Ventavis (iloprost) is equally effective in managing lingering high lung blood pressure after surgery for chronic thromboembolic pulmonary hypertension (CTEPH). A comparison of the two treatments — published in the journal General Thoracic and Cardiovascular Surgery under the title, “A prospective, randomized study…

Balloon pulmonary angioplasty (BPA) led to significant clinical improvements for people with chronic thromboembolic pulmonary hypertension (CTEPH) when used as an initial therapy or after a pulmonary endarterectomy (PEA) surgery, according to a global observational study. “Our data are in line with previous reports on changes of clinical and…

https://www.youtube.com/watch?v=WQnQxSoPkC8 In this video from Experts On CTEPH, Dr. Raymond L. Benza, MD, of Allegheny General Hospital, Pittsburgh, talks about the differential diagnosis of CTEPH. He defines the diseases, explains the symptoms and details how the diagnosis should be made. Learn more about…